Developer docs
API playgroundTry for free, no card

Search company profiles

Amylyx Pharmaceuticals

Full company profile

uuid00003hg

Namestring
Amylyx Pharmaceuticals
Legal namestring
Amylyx Pharmaceuticals, Inc.
Websiteurl
amylyx.com
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and neurodegenerative diseases with high unmet medical need. The company was founded in 2013 by Josh Cohen and Justin Klee and completed its initial public offering on NASDAQ under the ticker AMLX in January 2022. Its pipeline is modality-agnostic and currently comprises four investigational programs: avexitide, a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol targeting endoplasmic reticulum stress and mitochondrial dysfunction, being developed for Wolfram syndrome; AMX0114, an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis (ALS); and AMX0318, a long-acting GLP-1 receptor antagonist being developed in collaboration with Gubra A/S.

The company's core value driver is avexitide, which was acquired from Eiger BioPharmaceuticals in July 2024 and is being evaluated in the pivotal Phase 3 LUCIDITY trial in PBH, with enrollment of 78 participants completed in March 2026 and topline data expected in Q3 2026. If positive, Amylyx plans an immediate NDA submission and a potential 2027 U.S. commercial launch into a market of approximately 160,000 U.S. PBH patients with no FDA-approved therapies. AMX0035, AMX0114, and AMX0318 provide optionality across Wolfram syndrome, ALS, and next-generation GLP-1 antagonism respectively, supported by Orphan Drug, Breakthrough Therapy, and Fast Track regulatory designations.

The business model is currently a pre-commercial clinical-development model. The company previously generated product revenue from RELYVRIO/ALBRIOZA (AMX0035) for ALS in the U.S. and Canada following FDA approval in September 2022, but voluntarily withdrew the product in April 2024 after the Phase 3 PHOENIX trial failed to meet its primary endpoint, triggering a roughly 70% workforce reduction. Commercialization strategy for avexitide includes a U.S. specialty pharmacy and rare-disease field force model, with a Chief Commercial Officer (Dan Monahan) hired in preparation for a 2027 launch. As of May 2026, Teva Pharmaceutical Industries announced an agreement to acquire Amylyx for $700 million upfront plus up to $200 million in milestone payments, with closing expected in late Q2 or early Q3 2026, which would end Amylyx's status as an independent public company.

Short descriptiontext

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases, with lead candidate avexitide in Phase 3 development for post-bariatric hypoglycemia and additional programs in Wolfram syndrome and ALS.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, clinical stage biopharmaceutical, neurology drug development, endocrine disorder therapies, antisense oligonucleotide therapy
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Rare Disease Biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Drug commercialization (planned — avexitide)
TypeOne Time License
Description

Amylyx is preparing for potential commercial launch of avexitide in 2027 for post-bariatric hypoglycemia. No FDA-approved therapies currently exist for PBH, representing a potential first-in-class opportunity. Avexitide would be commercialized as a prescription pharmaceutical product administered via subcutaneous injection. The company has a Chief Commercial Officer (Dan Monahan) and is conducting NDA-readiness preparations.

businesswire.com
2Former commercial product (discontinued — RELYVRIO)
TypeOne Time License
Description

Amylyx previously generated product revenue from RELYVRIO (AMX0035) in the U.S. and ALBRIOZA in Canada for ALS treatment. Revenue was generated through product sales to patients and payers. Following the Phase 3 PHOENIX trial failure in March-April 2024, the company voluntarily discontinued marketing authorizations for both products in the U.S. and Canada and provided free drug access through early 2025 to patients who chose to continue therapy. This revenue stream is no longer active.

biospace.com
3Potential acquisition proceeds
TypeTransaction Fee
Description

In May 2026, Teva Pharmaceutical Industries announced agreement to acquire Amylyx Pharmaceuticals for $700 million upfront plus up to $200 million in milestone payments, expected to close in late Q2 or early Q3 2026. If completed, this would represent a significant liquidity event, though it would end Amylyx as an independent public company.

in.investing.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Pricing details1 tier
1Avexitide Expanded Access Program (EAP) — investigational drug at no cost to eligible patients
ModelOtherBilling cadencePay-as-you-go
Notes

The Amylyx Access Program for avexitide provides the investigational drug at no charge to qualifying U.S. patients with PBH following RYGB who have serious unmet medical need, are unable to participate in an ongoing clinical trial, and have exhausted available treatment options. EAP is subject to FDA review and authorization; participation is not guaranteed.

businesswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1ALBRIOZA
Description

Brand name for AMX0035 approved in Canada (with conditions) for ALS treatment

amylyx.com
+1 more record
Core offering1 text field

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases. Its pipeline includes avexitide (a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia), AMX0035 (oral fixed-dose combination of sodium phenylbutyrate and taurursodiol for Wolfram syndrome), AMX0114 (antisense oligonucleotide targeting calpain-2 for ALS), and AMX0318 (long-acting GLP-1 receptor antagonist). The company is preparing for a potential 2027 commercial launch of avexitide in the U.S.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Avexitide demonstrated statistically significant reductions in hypoglycemic events in 5 prior Phase 1 and Phase 2 clinical trials in PBH, with over 50% reduction in daily rates of hypoglycemia in Phase 2 trials.
+3 more records
Product overview1 text field

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing four investigational therapies across endocrine conditions and neurodegenerative diseases: Avexitide (GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism), AMX0035 (oral combination for Wolfram syndrome), AMX0114 (antisense oligonucleotide for ALS), and AMX0318 (long-acting GLP-1 receptor antagonist for PBH). These are drugs in clinical development, not commercial software products.

Product and service4 records
1Avexitide
CategoryInvestigational Biopharmaceutical (Peptide)
Description

Avexitide is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist injectable peptide designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of excessive GLP-1 to mitigate hypoglycemia. It is being developed for post-bariatric hypoglycemia (PBH) following bariatric surgery and congenital hyperinsulinism (HI). It holds FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation.

2AMX0035
CategoryInvestigational Biopharmaceutical (Small Molecule Combination)
Description

AMX0035 is an oral fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), two small molecules that target endoplasmic reticulum (ER) stress and mitochondrial dysfunction — the two cellular processes central to neuronal cell death and neurodegeneration. It is being developed for Wolfram syndrome and received FDA and European Commission Orphan Drug Designations.

3AMX0114
CategoryInvestigational Biopharmaceutical (Antisense Oligonucleotide)
Description

AMX0114 is an antisense oligonucleotide (ASO) administered intrathecally that targets calpain-2 (CAPN2), a calcium-dependent protease and critical effector of axonal (Wallerian) degeneration in ALS and other neurodegenerative diseases. AMX0114 cleaves neurofilament light chain (NfL) and TDP-43, proteins associated with ALS pathology. It received FDA Fast Track Designation for ALS in May 2025.

4AMX0318
CategoryInvestigational Biopharmaceutical (Long-Acting Peptide)
Description

AMX0318 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist identified through Amylyx's research collaboration with Gubra A/S. It has completed extensive preclinical evaluation including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability studies. It is being developed for post-bariatric hypoglycemia and other rare diseases.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Amylyx entered a research collaboration with Danish biotech company Gubra A/S (December 2024) to develop a novel long-acting GLP-1 receptor antagonist. Through this collaboration, AMX0318 was selected as a development candidate for post-bariatric hypoglycemia and other rare diseases. Gubra is an industry leader in peptide-based drug discovery. Amylyx has exclusive rights to development candidates identified through the collaboration. Gubra is eligible to receive over $50 million in success-based milestones plus mid-single digit royalties, including a $4 million payment for AMX0318 candidate selection. IND-enabling studies for AMX0318 are underway with an IND targeted for 2027.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-07-01
Description

Amylyx acquired avexitide (a Phase 3-ready GLP-1 receptor antagonist) from Eiger BioPharmaceuticals in July 2024 for an undisclosed upfront amount. Avexitide had been developed by Eiger for post-bariatric hypoglycemia and congenital hyperinsulinism, receiving FDA Breakthrough Therapy Designation and Orphan Drug Designation. The acquisition added a near-commercial asset to Amylyx's pipeline, representing the company's strategic pivot from ALS following the RELYVRIO withdrawal.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CNS specialty biopharma with a similar profile of a single approved CNS drug, post-launch setbacks, and pipeline pivots — making it a close comparable in CNS rare-disease commercial and development cycles.

TypeBroad incumbent
Description

Rare-disease focused biopharma with multiple programs across different modalities and small patient populations — a structural comparable for Amylyx's multi-asset rare-disease thesis.

TypeBroad incumbent
Description

Nucleotide-based (RNAi) rare-disease drug developer with regulatory designations and rare-disease commercial infrastructure; comparable for Amylyx's oligonucleotide direction and rare metabolic disease focus.

TypeEmerging player
Description

Gene therapy platform company with CNS-directed rare disease programs and selective modality use — comparable in CNS rare-disease therapeutic ambition and pipeline approach.

TypeBroad incumbent
Description

Established rare-disease specialty pharmaceutical company with a multi-asset rare-disease portfolio and global commercial infrastructure — a relevant incumbent comparable for Amylyx's planned rare-endocrine and neurodegenerative launches.

TypeDirect peer
Description

Original developer and licensor of avexitide (the GLP-1 receptor antagonist that became Amylyx's lead asset after Amylyx acquired it in July 2024). Directly comparable in target indications (PBH, congenital hyperinsulinism) and mechanistic approach.

TypeEmerging player
Description

Cardiac and CNS gene therapy clinical-stage biotech with CNS-directed rare-disease programs — comparable as a small rare-disease biotech advancing oligonucleotide/gene-therapy modalities into rare indications.

TypeDirect peer
Description

Antisense oligonucleotide (ASO) platform company most directly comparable to Amylyx's AMX0114 (calpain-2 ASO) program for ALS; both develop intrathecally administered CNS-directed ASOs for rare neurological indications.

TypeEmerging player
Description

Clinical-stage rare-disease biotech with a CNS/spinal muscular atrophy focus and platform technology — comparable in size, stage, and late-stage clinical development priorities.

TypeBroad incumbent
Description

Rare-disease biotech with multiple modalities (biologics, ASO, gene therapy) targeting metabolic and neurological rare diseases — closely comparable platform breadth and pipeline to Amylyx's modality-agnostic strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amylyx Pharmaceuticals

Clinical-Stage Rare Disease Biopharmaceuticalsamylyx.com

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases, with lead candidate avexitide in Phase 3 development for post-bariatric hypoglycemia and additional programs in Wolfram syndrome and ALS.

What Amylyx Pharmaceuticals does

Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for rare endocrine and neurodegenerative diseases with high unmet medical need. The company was founded in 2013 by Josh Cohen and Justin Klee and completed its initial public offering on NASDAQ under the ticker AMLX in January 2022. Its pipeline is modality-agnostic and currently comprises four investigational programs: avexitide, a first-in-class GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism; AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol targeting endoplasmic reticulum stress and mitochondrial dysfunction, being developed for Wolfram syndrome; AMX0114, an antisense oligonucleotide targeting calpain-2 for amyotrophic lateral sclerosis (ALS); and AMX0318, a long-acting GLP-1 receptor antagonist being developed in collaboration with Gubra A/S.

The company's core value driver is avexitide, which was acquired from Eiger BioPharmaceuticals in July 2024 and is being evaluated in the pivotal Phase 3 LUCIDITY trial in PBH, with enrollment of 78 participants completed in March 2026 and topline data expected in Q3 2026. If positive, Amylyx plans an immediate NDA submission and a potential 2027 U.S. commercial launch into a market of approximately 160,000 U.S. PBH patients with no FDA-approved therapies. AMX0035, AMX0114, and AMX0318 provide optionality across Wolfram syndrome, ALS, and next-generation GLP-1 antagonism respectively, supported by Orphan Drug, Breakthrough Therapy, and Fast Track regulatory designations.

The business model is currently a pre-commercial clinical-development model. The company previously generated product revenue from RELYVRIO/ALBRIOZA (AMX0035) for ALS in the U.S. and Canada following FDA approval in September 2022, but voluntarily withdrew the product in April 2024 after the Phase 3 PHOENIX trial failed to meet its primary endpoint, triggering a roughly 70% workforce reduction. Commercialization strategy for avexitide includes a U.S. specialty pharmacy and rare-disease field force model, with a Chief Commercial Officer (Dan Monahan) hired in preparation for a 2027 launch. As of May 2026, Teva Pharmaceutical Industries announced an agreement to acquire Amylyx for $700 million upfront plus up to $200 million in milestone payments, with closing expected in late Q2 or early Q3 2026, which would end Amylyx's status as an independent public company.

Amylyx Pharmaceuticals firmographics

Firmographics
Name
Amylyx Pharmaceuticals
Legal name
Amylyx Pharmaceuticals, Inc.
Website
https://amylyx.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases, with lead candidate avexitide in Phase 3 development for post-bariatric hypoglycemia and additional programs in Wolfram syndrome and ALS.
Ownership category
akta.pro rank

Amylyx Pharmaceuticals industry classification

Industry
Product category
Clinical-Stage Rare Disease Biopharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Rare disease therapeutics
  • Clinical stage biopharmaceutical
  • Neurology drug development
  • Endocrine disorder therapies
  • Antisense oligonucleotide therapy

Where Amylyx Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Amylyx Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Drug commercialization (planned — avexitide): Amylyx is preparing for potential commercial launch of avexitide in 2027 for post-bariatric hypoglycemia. No FDA-approved therapies currently exist for PBH, representing a potential first-in-class opportunity. Avexitide would be commercialized as a prescription pharmaceutical product administered via subcutaneous injection. The company has a Chief Commercial Officer (Dan Monahan) and is conducting NDA-readiness preparations.
  2. Former commercial product (discontinued — RELYVRIO): Amylyx previously generated product revenue from RELYVRIO (AMX0035) in the U.S. and ALBRIOZA in Canada for ALS treatment. Revenue was generated through product sales to patients and payers. Following the Phase 3 PHOENIX trial failure in March-April 2024, the company voluntarily discontinued marketing authorizations for both products in the U.S. and Canada and provided free drug access through early 2025 to patients who chose to continue therapy. This revenue stream is no longer active.
  3. Potential acquisition proceeds: In May 2026, Teva Pharmaceutical Industries announced agreement to acquire Amylyx Pharmaceuticals for $700 million upfront plus up to $200 million in milestone payments, expected to close in late Q2 or early Q3 2026. If completed, this would represent a significant liquidity event, though it would end Amylyx as an independent public company.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goAvexitide Expanded Access Program (EAP) — investigational drug at no cost to eligible patients

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Amylyx Pharmaceuticals product offering

Product offering

Core offering

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases. Its pipeline includes avexitide (a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia), AMX0035 (oral fixed-dose combination of sodium phenylbutyrate and taurursodiol for Wolfram syndrome), AMX0114 (antisense oligonucleotide targeting calpain-2 for ALS), and AMX0318 (long-acting GLP-1 receptor antagonist). The company is preparing for a potential 2027 commercial launch of avexitide in the U.S.

Product overview

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing four investigational therapies across endocrine conditions and neurodegenerative diseases: Avexitide (GLP-1 receptor antagonist for post-bariatric hypoglycemia and congenital hyperinsulinism), AMX0035 (oral combination for Wolfram syndrome), AMX0114 (antisense oligonucleotide for ALS), and AMX0318 (long-acting GLP-1 receptor antagonist for PBH). These are drugs in clinical development, not commercial software products.

Differentiator

Problem solved

Functional benefit

Brands

  • ALBRIOZA: Brand name for AMX0035 approved in Canada (with conditions) for ALS treatment
  • RELYVRIO

Products and services

  • Avexitide Avexitide is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist injectable peptide designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of excessive GLP-1 to mitigate hypoglycemia. It is being developed for post-bariatric hypoglycemia (PBH) following bariatric surgery and congenital hyperinsulinism (HI). It holds FDA Breakthrough Therapy Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation.
  • AMX0035 AMX0035 is an oral fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO), two small molecules that target endoplasmic reticulum (ER) stress and mitochondrial dysfunction — the two cellular processes central to neuronal cell death and neurodegeneration. It is being developed for Wolfram syndrome and received FDA and European Commission Orphan Drug Designations.
  • AMX0114 AMX0114 is an antisense oligonucleotide (ASO) administered intrathecally that targets calpain-2 (CAPN2), a calcium-dependent protease and critical effector of axonal (Wallerian) degeneration in ALS and other neurodegenerative diseases. AMX0114 cleaves neurofilament light chain (NfL) and TDP-43, proteins associated with ALS pathology. It received FDA Fast Track Designation for ALS in May 2025.
  • AMX0318 AMX0318 is a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist identified through Amylyx's research collaboration with Gubra A/S. It has completed extensive preclinical evaluation including stability, solubility, potency, in vivo pharmacokinetics and pharmacodynamics, and tolerability studies. It is being developed for post-bariatric hypoglycemia and other rare diseases.

Quantifiable outcome

  • Avexitide demonstrated statistically significant reductions in hypoglycemic events in 5 prior Phase 1 and Phase 2 clinical trials in PBH, with over 50% reduction in daily rates of hypoglycemia in Phase 2 trials.
  • +3 more outcomes

Companies that use Amylyx Pharmaceuticals

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Amylyx Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Amylyx Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Gubra A/ScoreStrategic or Co-development Partner · 1 December 2024Amylyx entered a research collaboration with Danish biotech company Gubra A/S (December 2024) to develop a novel long-acting GLP-1 receptor antagonist. Through this collaboration, AMX0318 was selected as a development candidate for post-bariatric hypoglycemia and other rare diseases. Gubra is an industry leader in peptide-based drug discovery. Amylyx has exclusive rights to development candidates identified through the collaboration. Gubra is eligible to receive over $50 million in success-based milestones plus mid-single digit royalties, including a $4 million payment for AMX0318 candidate selection. IND-enabling studies for AMX0318 are underway with an IND targeted for 2027.
  • Eiger BioPharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 1 July 2024Amylyx acquired avexitide (a Phase 3-ready GLP-1 receptor antagonist) from Eiger BioPharmaceuticals in July 2024 for an undisclosed upfront amount. Avexitide had been developed by Eiger for post-bariatric hypoglycemia and congenital hyperinsulinism, receiving FDA Breakthrough Therapy Designation and Orphan Drug Designation. The acquisition added a near-commercial asset to Amylyx's pipeline, representing the company's strategic pivot from ALS following the RELYVRIO withdrawal.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Amylyx Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Sage Therapeutics: CNS specialty biopharma with a similar profile of a single approved CNS drug, post-launch setbacks, and pipeline pivots — making it a close comparable in CNS rare-disease commercial and development cycles.
  • Eiger BioPharmaceuticals: Original developer and licensor of avexitide (the GLP-1 receptor antagonist that became Amylyx's lead asset after Amylyx acquired it in July 2024). Directly comparable in target indications (PBH, congenital hyperinsulinism) and mechanistic approach.
  • Ionis Pharmaceuticals: Antisense oligonucleotide (ASO) platform company most directly comparable to Amylyx's AMX0114 (calpain-2 ASO) program for ALS; both develop intrathecally administered CNS-directed ASOs for rare neurological indications.

Broad incumbents

  • BridgeBio Pharma: Rare-disease focused biopharma with multiple programs across different modalities and small patient populations — a structural comparable for Amylyx's multi-asset rare-disease thesis.
  • Alnylam Pharmaceuticals: Nucleotide-based (RNAi) rare-disease drug developer with regulatory designations and rare-disease commercial infrastructure; comparable for Amylyx's oligonucleotide direction and rare metabolic disease focus.
  • BioMarin Pharmaceutical: Established rare-disease specialty pharmaceutical company with a multi-asset rare-disease portfolio and global commercial infrastructure — a relevant incumbent comparable for Amylyx's planned rare-endocrine and neurodegenerative launches.
  • Ultragenyx Pharmaceutical: Rare-disease biotech with multiple modalities (biologics, ASO, gene therapy) targeting metabolic and neurological rare diseases — closely comparable platform breadth and pipeline to Amylyx's modality-agnostic strategy.

Emerging players

  • Regenxbio: Gene therapy platform company with CNS-directed rare disease programs and selective modality use — comparable in CNS rare-disease therapeutic ambition and pipeline approach.
  • Lexeo Therapeutics: Cardiac and CNS gene therapy clinical-stage biotech with CNS-directed rare-disease programs — comparable as a small rare-disease biotech advancing oligonucleotide/gene-therapy modalities into rare indications.
  • Scholar Rock: Clinical-stage rare-disease biotech with a CNS/spinal muscular atrophy focus and platform technology — comparable in size, stage, and late-stage clinical development priorities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Amylyx Pharmaceuticals social profiles

Digital presence

Amylyx Pharmaceuticals compliance and trust

Trust signal

Compliance4 records

Amylyx Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amylyx Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles15 records

Amylyx Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Amylyx Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amylyx Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amylyx Pharmaceuticals

What does Amylyx Pharmaceuticals do?

Amylyx Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational therapies for rare endocrine and neurodegenerative diseases. Its pipeline includes avexitide (a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia), AMX0035 (oral fixed-dose combination of sodium phenylbutyrate and taurursodiol for Wolfram syndrome), AMX0114 (antisense oligonucleotide targeting calpain-2 for ALS), and AMX0318 (long-acting GLP-1 receptor antagonist). The company is preparing for a potential 2027 commercial launch of avexitide in the U.S.

Is Amylyx Pharmaceuticals a public or private company?

Amylyx Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Amylyx Pharmaceuticals founded?

Amylyx Pharmaceuticals was founded in 2013. It employs 101 to 250 people.

Where is Amylyx Pharmaceuticals based?

Amylyx Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

How does Amylyx Pharmaceuticals make money?

Three revenue lines are on record. Drug commercialization (planned — avexitide) is the primary driver. The others are former commercial product (discontinued — RELYVRIO) and potential acquisition proceeds.

Who are Amylyx Pharmaceuticals's main competitors?

Direct peers on record are Sage Therapeutics, Eiger BioPharmaceuticals and Ionis Pharmaceuticals. Broad incumbents are BridgeBio Pharma, Alnylam Pharmaceuticals, BioMarin Pharmaceutical and Ultragenyx Pharmaceutical. Emerging players are Regenxbio, Lexeo Therapeutics and Scholar Rock.

Does Amylyx Pharmaceuticals have an API?

No public API is recorded for Amylyx Pharmaceuticals.

What industry is Amylyx Pharmaceuticals in?

Amylyx Pharmaceuticals's product category is Clinical-Stage Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Amylyx Pharmaceuticals at Buy, keeps price target at $55HC Wainwright & Co. maintained Amylyx Pharmaceuticals at Buy and kept its price target at $55. The target implies an upside of 106.6% from the Nov 18 close of $26.62. The firm's rating and price target are unchanged.Longevity.TechnologyAmylyx drug cuts severe low blood sugar events by 55%Amylyx Pharmaceuticals reported Phase 3 LUCIDITY trial results for Avexitide in post-bariatric hypoglycemia, showing a 55% reduction in Level 2 and 3 hypoglycemic events versus placebo over 16 weeks. The composite rate was 0.55 events per week with Avexitide versus 1.24 with placebo (p=0.0000034). The company said the trial met its prespecified primary endpoint.YahooAmylyx reveals data from Phase III LUCIDITY trial of avexitideAmylyx Pharmaceuticals reported Phase III LUCIDITY trial data for avexitide in post-bariatric hypoglycaemia, showing a 55% reduction in hypoglycemic events versus placebo. The study met all prespecified secondary endpoints, with completion rates exceeding 90% and no serious adverse events.Seeking AlphaAmylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia TranscriptAmylyx Pharmaceuticals presented LUCIDITY results and discussed avexitide, a first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation, for post-bariatric hypoglycemia. The company highlighted the unmet need and ongoing clinical challenges in the condition.The future of tradingAmylyx's avexitide reduces hypoglycemic event rate by 55% in Phase 3 trialAmylyx Pharmaceuticals will present Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek 2026 on November 15. The drug significantly reduced hypoglycemic events versus placebo, meeting the primary endpoint and all prespecified secondary event-rate endpoints. A U.S. marketing application is targeted by year-end, with a potential commercial launch in 2027 if approved.The future of tradingAmylyx Pharmaceuticals Publishes Presentation on Phase 3 Avexitide Trial ResultsAmylyx Pharmaceuticals published Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The drug reduced composite level 2/3 hypoglycemic event rates by 55% versus placebo, meeting the primary endpoint (p=0.0000034). Secondary endpoints were also met, with event reductions ranging from 42% to 63%.TradingViewAmylyx Pharmaceuticals (AMLX) Reports 55% Fewer Hypoglycemic Events Versus PlaceboAmylyx Pharmaceuticals reported that its Phase 3 LUCIDITY trial met its primary endpoint, reducing the composite rate of Level 2 and Level 3 hypoglycemic events by 55% versus placebo over 16 weeks (0.55 vs 1.24 events per week; p=0.0000034). The company is moving toward an NDA submission by year end.Simply Wall StHow Investors May Respond To Amylyx Pharmaceuticals Stock After Wider Q3 LossAmylyx Pharmaceuticals reported a Q3 2026 net loss of $45.49 million and a nine-month loss of $130.2 million, with loss per share of $0.38 and $1.15 respectively. The widening losses reflect continued investment in its pre-revenue pipeline, with analysts projecting $343.4 million revenue by 2029.Simply Wall StAmylyx Pharmaceuticals (AMLX) Tests Its Undervalued Narrative On Third Quarter LossesAmylyx Pharmaceuticals reported a Q3 net loss of $45.49 million and a basic loss per share of $0.38. Its share price rose 161.47% year-to-date to $29.86, while analysts set a consensus fair value of $42.36, implying undervaluation. The stock's future depends heavily on avexitide and the LUCIDITY Phase 3 outcome.Defense WorldMizuho Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock PriceMizuho raised its Amylyx Pharmaceuticals price target to $39.00 from $38.00, keeping an outperform rating. The stock opened at $30.91, with a consensus target of $43.71 and an average Buy rating. Analysts expect a loss of $1.48 per share for the current year.